10 years ago when my dad was treated for prostate cancer he was only offered 2 treatment options...
Today the prostate therapy landscape looks completely different...
One of the worst things any of us will hear is when a loved one receives a cancer diagnosis. However, things are starting to look much more positive for men who will experience prostate cancer in their lives, which is the vast majority of us. The level of innovation happening across prostate care right now is remarkable, and from a market perspective the direction of travel is becoming very clear.
Across both BPH and prostate cancer, treatment is shifting toward three key principles: less invasive, more precise and better preservation of function. Or put simply: treat the disease without unnecessarily damaging everything around it.
As someone who works closely with the medtech market, prostate therapy has quietly become one of the most fascinating technology races to watch.
The outpatient revolution has already started
BPH paved the way. Companies like Boston Scientific (CEO: Mike Mahoney ) helped move prostate procedures toward outpatient settings with technologies such as Rezūm™ and GreenLight™, shifting treatment away from traditional theatre-heavy pathways.
Now we’re starting to see that same philosophy extend into cancer care. Francis Medical (CEO: Mike Kujak) recently secured FDA clearance for Vanquish® for intermediate-risk prostate cancer — a clear signal that incisionless, energy-based therapies are expanding their role beyond BPH and into oncology.
Health systems like it. Patients definitely like it. And very few people ever say: “I wish my treatment required a longer hospital stay.” Like most outpatient treatments, reimbursement remains the final challenge to overcome, but there is movement starting to happen.
Precision is becoming the real battleground
For decades, prostate treatment has faced two core challenges: knowing exactly where to treat and avoiding damage to critical surrounding anatomy. That’s where the next generation of platforms is changing the equation.
One of the most interesting areas to watch right now is image-guided focal therapy. EDAP TMS (CEO: Ryan Rhodes) with Focal One® is a strong example of where the field is heading, combining robotic HIFU with image-guided targeting and increasingly intelligent treatment planning. When procedures become mapped, visualised and software-assisted, something important happens: outcomes become less dependent on operator variability and more dependent on platform consistency. And in healthcare, consistency tends to win adoption.
Profound Medical (CEO: Arun Menawat) is also advancing the precision category with TULSA-PRO®, combining MRI guidance with real-time thermometry and closed-loop control.
Another company generating interest is Nina Medical (CEO: Shmuel Ben-Ezra), which is developing ultrasound-based therapeutic technologies designed to improve precision tissue targeting while protecting surrounding anatomy, another signal that energy-based focal therapy continues to evolve.
Koelis (CEO: Antoine Leroy ) is a company to watch on the imaging and navigation side. Their Trinity® prostate fusion biopsy platform integrates MRI and ultrasound imaging to help map lesions more precisely, a critical piece of the broader precision-therapy ecosystem.
Companies like Avenda Health (CEO: Shyam Natarajan ) are combining AI-driven cancer mapping with targeted therapy planning. Their work highlights a growing role for data and decision-support software in prostate treatment pathways.
Zoom out and the pattern is clear: prostate therapy is becoming image-guided precision therapy.
Robotics is splitting into two futures
Robotics in prostate care is no longer one story — it’s two.
Remove the prostate/cancerous tissue: Intuitive Surgical (CEO: Dave Rosa) remains the global benchmark for robotic prostatectomy with the da Vinci platform.
Target the problem: PROCEPT BioRobotics (CEO: Larry Wood) brings robotic precision to BPH treatment with Aquablation®, a heat-free waterjet approach designed to improve consistency of tissue removal.
Both approaches will remain important as they focus on different patient populations. If you follow the innovation momentum, a lot of energy is clearly building around precision focal treatment strategies that treat the disease while preserving surrounding structures. As robotic systems continue to become more precise, they will continue to play a significant role.
Where the market appears to be heading
Looking at the broader innovation landscape, three themes are emerging as likely defining features of the future prostate pathway: image-guided focal therapy ecosystems (MRI/ultrasound fusion plus intelligent planning and controlled energy delivery), software-defined procedures (planning → execution → validation), and outpatient-first treatment models that reduce resource intensity while improving recovery and patient experience.
Healthcare systems increasingly prioritise consistency and reproducibility. This model has already proven itself in BPH, and the next phase is seeing how far it expands into prostate cancer treatment pathways.
Why this progress matters
Seeing how much the treatment landscape has evolved since my dad’s diagnosis ten years ago makes this innovation feel very real. Back then the choices felt limited, but today patients are entering a far more sophisticated conversation about treatment, one that increasingly includes precision, personalisation and preservation of quality of life.
From a market perspective, prostate care is quickly becoming one of the most interesting intersections of imaging, robotics, software and energy-based therapy in medtech and it feels like we’re only just getting started.
Interested to hear perspectives from clinicians, founders and investors in this space:
Which technology platform do you think will ultimately define the next generation of prostate therapy focal therapy, MRI-guided systems, robotics, or something else entirely?
%20(1).png)
